文献速递炎症性肠病

系统综述与Meta分析:口服Janus激酶抑制剂治疗炎症性肠病的疗效与安全性

Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2019-05-23

该系统综述与Meta分析纳入12项随机安慰剂对照试验,评估JAK抑制剂治疗克罗恩病和溃疡性结肠炎的疗效与安全性。JAK抑制剂可诱导CD临床缓解及UC临床和內镜下缓解,但感染风险较安慰剂增加,尤其是带状疱疹。

要点

  • JAK抑制剂诱导CD临床缓解的RR为1.38(95%CI 1.04-1.83),P=0.025。
  • JAK抑制剂诱导UC临床缓解的RR为3.07(95%CI 2.03-4.63),P<0.001。
  • JAK抑制剂较安慰剂增加感染风险(RR 1.40,95%CI 1.18-1.67),尤其带状疱疹。

核心结论

  • JAK抑制剂可有效诱导CD临床缓解以及UC临床和内镜下缓解,但与感染并发症风险增加相关。

研究设计与样本

  • 系统检索PubMed、Embase和CENTRAL至2018年11月1日,纳入成人CD或UC的JAK抑制剂随机安慰剂对照试验,排除无安慰剂对照的开放标签扩展研究,采用随机效应模型合并率。
  • 共纳入12项随机对照试验(5项CD,7项UC),患者随机分配至安慰剂(n=844)、托法替布(n=1882)、filgotinib(n=130)、peficitinib(n=176)、upadacitinib(n=387)或TD-1473(n=31)。

主要发现

  • JAK抑制剂诱导CD临床缓解的RR为1.38(95%CI 1.04-1.83),P=0.025,I²=14%。
  • JAK抑制剂诱导UC临床缓解的RR为3.07(95%CI 2.03-4.63),P<0.001,I²=0%。
  • UC中,JAK抑制剂诱导内镜下缓解(内镜Mayo子评分MCSe=0/1)的RR为2.43(95%CI 1.64-3.59),P<0.001,I²=27%。
  • UC中,JAK抑制剂诱导黏膜愈合(MCSe=0)的RR为5.50(95%CI 2.46-12.32),P<0.001,I²=0%。
  • JAK抑制剂较安慰剂增加感染风险(RR 1.40,95%CI 1.18-1.67),P<0.001,I²=0%,尤其是带状疱疹。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Janus kinase (JAK) inhibitors represent a novel therapeutic class for treatment of inflammatory bowel disease. AIMS: To determine the efficacy and safety of JAK inhibitors compared to placebo for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). METHODS: PubMed, Embase and CENTRAL were systematically searched to November 1, 2018. Randomised placebo-controlled trials (RCTs) of JAK inhibitors in adult patients with CD or UC were eligible. Open-label extension studies without a placebo comparator arm were excluded. Clinical, endoscopic, and safety outcomes were extracted and rates relative to placebo were pooled using a random-effects model. RESULTS: A total of 12 RCTs (5 CD, 7 UC) were included. Patients were randomised to placebo (n = 844), tofacitinib (n = 1882), filgotinib (n = 130), peficitinib (n = 176), upadacitinib (n = 387) or TD-1473 (n = 31). JAK inhibitor treatment was associated with induction of clinical remission in CD (RR, relative risk 1.38 [95% confidence interval CI 1.04-1.83], P = 0.025, I2 = 14%) and UC (RR 3.07 [95% CI 2.03-4.63], P < 0.001, I2 = 0%). In UC, JAK inhibitor treatment was associated with induction of endoscopic remission (endoscopic Mayo subscore MCSe = 0/1) (RR 2.43 [95% CI 1.64-3.59], P < 0.001, I2 = 27%) and mucosal healing (MCSe = 0) (RR 5.50 [95% CI 2.46-12.32], P < 0.001, I2 = 0%). JAK inhibitor treatment increased the risk of infection compared to placebo (RR 1.40 [95% CI 1.18-1.67], P < 0.001, I2 = 0%), particularly for herpes zoster. CONCLUSIONS: JAK inhibitors are effective for inducing clinical remission in CD and induction of clinical and endoscopic remission in UC, although are associated with an increased risk of infectious complications.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ma C, Lee JK, Mitra AR, et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther. 2019. PMID: 31119766. doi:10.1111/apt.15297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。